Feinstein Spin-off Obtains $3M Grant
May 17, 2016
Long Island Business News
The Feinstein Institute for Medical Research said its spin-off TheraSource has received a $3 million three-year Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases.
The National Institutes of Health grant will support the development of human ghrelin to alleviate damage caused by unintentional radiation exposure.
The treatment, pioneered by research led by Dr. Ping Wan at the Feinstein, could be helpful to people who have been exposed to radiation in Chernobyl, Ukraine and Fukushima, Japan.
No treatment has yet been approved to counter gastrointestinal disease caused by higher doses of radiation, according to the institute.
The use of human ghrelin, a 28-amino acid peptide hormone, increased the survival rate and reduced the weight loss of animal models exposed to irradiation, according to Ping Wang, founder of TheraSource.
“One of our missions at the Feinstein Institute is to transition our lab discoveries onto the path of commercialization,” said Dr. Kevin Tracey, CEO of the Feinstein Institute. “TheraSource is an example of how we have successfully done this.”
May 12, 2016
TheraSource Snags $3M SBIR Grant